BVF PARTNERS L P/IL sold $5.5M of KYMR (indirect holdings)
BVF PARTNERS L P/IL sold 51,858 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at $106.50 ($5.52M total) on 2026-06-26.
How this was made
The 30-second read
Why it matters
The newest fact is the same-day open-market sale by a director via an indirect holding, totaling about $5.52M at $106.50/share.
Market read
Useful for tracking insider behavior, but it does not introduce new operational/financial guidance or regulatory/clinical catalysts.
What to watch
No 10b5-1 plan is stated, but the article also provides no context for why the sale occurred; traders should wait for additional insider buys/sells or company-specific news.
Background
This is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc.
Ticker impact
Kymera Therapeutics disclosed a Form 4: BVF Partners L P/IL (director) sold 51,858 shares at $106.50 on 2026-06-26 via an open-market sale.
Likely limited, short-lived impact; watch for follow-through in subsequent insider filings rather than a directional move.
Form 4 insider sales can be routine and are not accompanied here by new company fundamentals; the filing provides timing and size but no stated reason or guidance change.
Market effects
Minimal read-across; this is a single-company insider transaction with no sector-wide catalyst.
None.
None.
Counterpoint
The sale may be unrelated to fundamentals (liquidity/tax/portfolio rebalancing), especially since the filing does not indicate any adverse company event.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; director-related indirect holdings were reduced via an open-market sale.
- insiderBVF Partners L P/IL
Reporter on the Form 4; director role and sold 51,858 shares at $106.50 on 2026-06-26.
